Compare UPWK & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | DRTS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2018 | 2021 |
| Metric | UPWK | DRTS |
|---|---|---|
| Price | $8.81 | $15.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $22.73 | $8.67 |
| AVG Volume (30 Days) | ★ 3.7M | 577.4K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $787,784,000.00 | N/A |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $13.57 | $699.98 |
| P/E Ratio | $21.06 | ★ N/A |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $7.44 | $3.43 |
| 52 Week High | $22.84 | $15.10 |
| Indicator | UPWK | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 56.46 |
| Support Level | $8.48 | $11.24 |
| Resistance Level | $9.79 | $14.93 |
| Average True Range (ATR) | 0.30 | 0.60 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 89.06 | 50.69 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.